Goldman Sachs
XBI icon

Goldman Sachs’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Goldman Sachs’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$54M Buy
422,500
+261,100
+162% +$32.6M 0.01% 1520
2025
Q4 		$19.7M Sell
161,400
-1,430,000
-90% -$164M ﹤0.01% 2389
2025
Q3 		$159M Buy
1,591,400
+529,200
+50% +$47.7M 0.02% 698
2025
Q2 		$88.1M Buy
1,062,200
+898,300
+548% +$71.7M 0.01% 962
2025
Q1 		$13.3M Sell
163,900
-548,100
-77% -$49M ﹤0.01% 2424
2024
Q4 		$64.1M Sell
712,000
-968,000
-58% -$93.8M 0.01% 1093
2024
Q3 		$166M Buy
1,680,000
+759,000
+82% +$74.6M 0.03% 581
2024
Q2 		$85.4M Sell
921,000
-2,251,500
-71% -$202M 0.01% 879
2024
Q1 		$301M Buy
3,172,500
+211,900
+7% +$19.7M 0.05% 361
2023
Q4 		$264M Buy
2,960,600
+484,600
+20% +$36M 0.05% 396
2023
Q3 		$181M Buy
2,476,000
+218,100
+10% +$17.4M 0.04% 468
2023
Q2 		$188M Sell
2,257,900
-239,400
-10% -$20M 0.04% 452
2023
Q1 		$190M Buy
2,497,300
+1,148,700
+85% +$95.3M 0.04% 437
2022
Q4 		$112M Sell
1,348,600
-1,092,500
-45% -$88.4M 0.03% 673
2022
Q3 		$194M Buy
2,441,100
+397,300
+19% +$33.5M 0.05% 403
2022
Q2 		$152M Sell
2,043,800
-641,000
-24% -$48.1M 0.04% 498
2022
Q1 		$241M Sell
2,684,800
-2,455,100
-48% -$227M 0.05% 372
2021
Q4 		$575M Buy
5,139,900
+1,154,200
+29% +$139M 0.11% 157
2021
Q3 		$501M Buy
3,985,700
+3,791,000
+1,947% +$488M 0.11% 175
2021
Q2 		$26.4M Sell
194,700
-600,300
-76% -$78.9M 0.01% 1805
2021
Q1 		$108M Buy
795,000
+619,900
+354% +$92.8M 0.03% 609
2020
Q4 		$24.7M Buy
175,100
+60,100
+52% +$7.7M 0.01% 1680
2020
Q3 		$12.8M Sell
115,000
-199,100
-63% -$22.3M ﹤0.01% 2097
2020
Q2 		$35.2M Sell
314,100
-13,900
-4% -$1.37M 0.01% 1237
2020
Q1 		$25.4M Sell
328,000
-165,500
-34% -$14.7M 0.01% 1344
2019
Q4 		$46.9M Buy
493,500
+245,000
+99% +$21.2M 0.01% 1197
2019
Q3 		$18.9M Sell
248,500
-475,000
-66% -$39.5M 0.01% 1825
2019
Q2 		$63.5M Buy
723,500
+505,000
+231% +$43.1M 0.02% 986
2019
Q1 		$19.8M Buy
218,500
+135,000
+162% +$11.5M 0.01% 1878
2018
Q4 		$5.99M Sell
83,500
-385,900
-82% -$31.1M ﹤0.01% 2729
2018
Q3 		$45M Buy
469,400
+363,500
+343% +$35.2M 0.01% 1303
2018
Q2 		$10.1M Sell
105,900
-802,600
-88% -$73.8M ﹤0.01% 2407
2018
Q1 		$79.7M Sell
908,500
-191,700
-17% -$17.5M 0.02% 920
2017
Q4 		$93.4M Sell
1,100,200
-197,500
-15% -$16.5M 0.02% 836
2017
Q3 		$112M Buy
1,297,700
+19,800
+2% +$1.59M 0.03% 743
2017
Q2 		$98.6M Sell
1,277,900
-74,500
-6% -$5.28M 0.03% 776
2017
Q1 		$93.8M Sell
1,352,400
-427,600
-24% -$28.7M 0.03% 794
2016
Q4 		$105M Buy
1,780,000
+105,600
+6% +$6.52M 0.03% 744
2016
Q3 		$111M Sell
1,674,400
-700,900
-30% -$43.4M 0.03% 659
2016
Q2 		$128M Buy
2,375,300
+397,500
+20% +$21.8M 0.04% 534
2016
Q1 		$102M Sell
1,977,800
-850,400
-30% -$44.2M 0.03% 646
2015
Q4 		$199M Buy
2,828,200
+1,731,500
+158% +$118M 0.06% 349
2015
Q3 		$68.3M Sell
1,096,700
-238,300
-18% -$18.8M 0.02% 849
2015
Q2 		$112M Buy
1,335,000
+795,000
+147% +$61.8M 0.03% 585
2015
Q1 		$40.6M Buy
+540,000
New +$37.7M 0.01% 1247
2014
Q4 		– Sell
-600,000
Closed -$31.2M – 7336
2014
Q3 		$31.2M Buy
+600,000
New +$30.6M 0.01% 1445

Other funds holding XBI

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Goldman Sachs's XBI Position: Q1 2026 in Review

Goldman Sachs reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 31% in Q1 2026, selling an estimated $771M and leaving 13,719,344 shares worth $1.75B. The position accounts for 0.2% of the portfolio, ranked #80.

Goldman Sachs first reported a position in XBI in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.43B in Q4 2025. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Goldman Sachs held 13,719,344 shares of State Street SPDR S&P Biotech ETF worth $1.75B as of Q1 2026.
  • Goldman Sachs sold 6,177,074 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $771M.
  • State Street SPDR S&P Biotech ETF made up 0.2% of Goldman Sachs's portfolio in Q1 2026, its #80 holding.
  • Goldman Sachs first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's State Street SPDR S&P Biotech ETF position peaked at $2.43B in Q4 2025.
  • 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.